Research

Cellular

The use of dual and triple agonists was associated with a higher risk of any adverse events (RR 1.13; 95% CI: 1.08-1.19).

Clinicians should be aware of the potential for increased adverse events when prescribing incretin polyagonists.

StrongSupportsmedium confidence
However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19).
Zhi Hong Chan et al. · Cardiology in Review · 2026

Why this rating

Based on a systematic review and meta-analysis of randomized controlled trials.

Source

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis

Zhi Hong Chan et al. · Cardiology in Review · 2026

DOI 10.1097/crd.0000000000001209

Meta-analysis
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →